The role of L-carnitine in the pathogenesis of cardiomegaly in patients with chronic hemodialysis.

Kudoh, Yasuo; Shoji, Tetsuro; Oimatsu, Hiroshi; Yoshida, Shigeo; Kikuchi, Kenjiro; Ito, Osamu

doi:10.1253/jcj.47.1391

Cited by 33 publications

(21 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, we showed the desirable effects of L-carnitine treatment on cardiomegaly. The previous report [11] that plasma carnitine levels in HD patients were inversely correlated with the CTR strongly supports our results. Together, these findings indicate that L-carnitine treatment is beneficial to improve depressed cardiac function as well as cardiogenic symptoms.…”

Section: Discussionsupporting

confidence: 93%

“…Böhmer et al [8] found that the muscle carnitine content after dialysis in HD patients was only 10% of normal controls. Kudoh et al [11] suggested that carnitine deficiency was involved in the pathogenesis of cardiomegaly. Against this background, some groups [10,12,13] have reported beneficial effects of oral supplementation of high-dose (2 g/day) or low-dose (0.5 g/day) L-carnitine on dialysisassociated muscle symptoms.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effects of <i>L</i>-Carnitine Supplementation on Cardiac Morbidity in Hemodialyzed Patients

Matsumoto

Sato

Ohashi³

et al. 2000

Am J Nephrol

View full text Add to dashboard Cite

Cardiac diseases are well known among patients on maintenance hemodialysis (HD), and carnitine deficiency may be an important factor in cardiac morbidity. We studied the effects of low-dose L-carnitine treatment (500 mg/day) on chest symptoms (dyspnea on exertion, chest pain, palpitation), cardiac function, and left ventricular (LV) mass in 9 HD patients with reduced ejection fraction (EF). After 6 months of L-carnitine treatment, most patients had at least some improvement in chest symptoms, while LVEF was increased and LV mass was decreased. Carnitine fractions increased and reached plateaus at 2–3 times the baseline levels. These results suggest that prolonged low-dose L-carnitine treatment can improve the cardiac morbidity by restoring decreased carnitine tissue levels and impaired oxidation of FFA.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Introductionmentioning

confidence: 99%

Effects of <i>L</i>-Carnitine Supplementation on Cardiac Morbidity in Hemodialyzed Patients

Matsumoto

Sato

Ohashi³

et al. 2000

Am J Nephrol

View full text Add to dashboard Cite

show abstract

“…Therefore, a carnitine deficiency is evidently responsible, at least partially, for the LVH of such patients. The fact that hypocarnitinemia is a risk factor for the cardiomegaly of patients in this state 31 supports this assumption.…”

Section: Discussionmentioning

confidence: 61%

L-Carnitine Supplementation Decreases the Left Ventricular Mass in Patients Undergoing Hemodialysis

Sakurabayashi

Miyazaki

Yuasa

et al. 2008

Circ J

View full text Add to dashboard Cite

Background Patients on long-term hemodialysis become deficient in carnitine and are frequently treated with carnitine supplementation to offset their renal anemia, lipid abnormality and cardiac dysfunction. The therapeutic value of carnitine supplementation on left ventricular hypertrophy (LVH) in patients with normal cardiac systolic function remains uncertain. Methods and ResultsThe cardiac morphology and function of 10 patients given 10 mg/kg of L-carnitine orally, immediately after hemodialysis sessions 3 times per week for a 12-month period were compared with 10 untreated control patients. Using echocardiography, left ventricular fractional shortening (LVFS) and left ventricular mass index (LVMI) were measured before and after the study period. As a result, amounts of serum-free carnitine increased from 28.4±4.7 to 58.5±12.1 mol/L. The LVMI decreased significantly from 151.8±21.2 to 134.0±16.0 g/m 2 in treated patients (p<0.01), yet the LVMI in untreated control patients did not change significantly (ie, from 153.3±28.2 to 167.1±43.1 g/m 2 ). However, LVFS values remained unchanged in both groups. Although L-carnitine promoted a 31% reduction in erythropoietin requirements, hematocrit and blood pressure did not change during the study period. Conclusions Supplementation with L-carnitine induced regression of LVH in patients on hemodialysis, even for those with normal systolic function. (Circ J 2008; 72: 926 -931)

show abstract

“…It has also been reported that hypocarnitinemia is closely related to cardiomegaly and cardiac ischemia in these patients [6,7]. Therefore, an improvement in cardiac function of patients with chronic hemodialysis associated with carnitine therapy might be expected.…”

Section: Introductionmentioning

confidence: 91%

Hemodynamic Stabilizing Effects of <smlcap>L</smlcap>-Carnitine in Chronic Hemodialysis Patients

Kudoh¹,

Aoyama²,

Torii³

et al. 2013

Cardiorenal Med

View full text Add to dashboard Cite

Background: The effects of L-carnitine on the hemodynamic state of chronic hemodialysis patients have been debated. In order to clarify the effect of administered L-carnitine on cardiac function and hypotensive episodes during the hemodialysis procedure, a randomized double-blind placebo-controlled study was performed for 3 months. Methods and Results: Twenty stable outpatients undergoing hemodialysis treatment were divided into two groups: controls (placebo) and treated patients (L-carnitine 900 mg p.o. daily). After 3 months, cardiac function was reevaluated by echocardiography, and hypotensive episodes during hemodialysis were assessed. Free and acyl carnitine levels increased significantly from 22.3 ± 7.1 to 140.3 ± 57.5 μmol/l and from 15.8 ± 2.8 to 94.8 ± 50.4 μmol/l, respectively, in the treated group. The ejection fraction significantly increased from 61.8 ± 16.0 to 64.4 ± 13.8% (p < 0.05) in the treated group. However, there was no difference in other echocardiographic parameters between the two groups. Hypotensive episodes significantly decreased from 4.0 ± 1.7 to 1.3 ± 0.9 times per month (p < 0.05), although patients' body weight did not change significantly. Conclusions: Beneficial effects of L-carnitine on the hemodynamic state of chronic hemodialysis patients were observed. L-Carnitine supplementation might be considered especially for chronic hemodialysis patients with unstable hemodynamic conditions.

show abstract

The role of L-carnitine in the pathogenesis of cardiomegaly in patients with chronic hemodialysis.

Cited by 33 publications

References 15 publications

Effects of <i>L</i>-Carnitine Supplementation on Cardiac Morbidity in Hemodialyzed Patients

Effects of <i>L</i>-Carnitine Supplementation on Cardiac Morbidity in Hemodialyzed Patients

L-Carnitine Supplementation Decreases the Left Ventricular Mass in Patients Undergoing Hemodialysis

Hemodynamic Stabilizing Effects of <smlcap>L</smlcap>-Carnitine in Chronic Hemodialysis Patients

Contact Info

Product

Resources

About